VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Tops Revenue Estimates

VYNE Therapeutics Inc. (VYNE) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $3.08 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -15.79%. A quarter ago, it was expected that this company would post a loss of $0.24 per share when it actually produced a loss of $0.15, delivering a surprise of 37.50%. Over the last four quarters, the company ha ...